These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28045912)

  • 1. Claudin-Low Breast Cancer; Clinical & Pathological Characteristics.
    Dias K; Dvorkin-Gheva A; Hallett RM; Wu Y; Hassell J; Pond GR; Levine M; Whelan T; Bane AL
    PLoS One; 2017; 12(1):e0168669. PubMed ID: 28045912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
    Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
    Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
    Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
    Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Claudin 1 Expression Levels Affect miRNA Dynamics in Human Basal-Like Breast Cancer Cells.
    Majer A; Blanchard AA; Medina S; Booth SA; Myal Y
    DNA Cell Biol; 2016 Jul; 35(7):328-39. PubMed ID: 26982264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Claudins as prognostic factors of breast cancer].
    Szász MA
    Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
    Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
    Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin-16 reduces the aggressive behavior of human breast cancer cells.
    Martin TA; Harrison GM; Watkins G; Jiang WG
    J Cell Biochem; 2008 Sep; 105(1):41-52. PubMed ID: 18442037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Claudin 1 expression in basal-like breast cancer is related to patient age.
    Blanchard AA; Ma X; Dueck KJ; Penner C; Cooper SC; Mulhall D; Murphy LC; Leygue E; Myal Y
    BMC Cancer; 2013 May; 13():268. PubMed ID: 23721519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.
    Zhang X; Zhang Y; Yang Y; Niu M; Sun S; Ji H; Ma Y; Yao G; Jiang Y; Shan M; Zhang G; Pang D
    Cancer Epidemiol; 2012 Jun; 36(3):288-93. PubMed ID: 21889920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.
    Qin T; Zeng YD; Qin G; Xu F; Lu JB; Fang WF; Xue C; Zhan JH; Zhang XK; Zheng QF; Peng RJ; Yuan ZY; Zhang L; Wang SS
    Oncotarget; 2015 Oct; 6(32):33972-81. PubMed ID: 26378017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
    Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
    Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor intrinsic subtype is reflected in cancer-adjacent tissue.
    Casbas-Hernandez P; Sun X; Roman-Perez E; D'Arcy M; Sandhu R; Hishida A; McNaughton KK; Yang XR; Makowski L; Sherman ME; Figueroa JD; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2015 Feb; 24(2):406-14. PubMed ID: 25465802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
    Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
    Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer.
    Di Cello F; Cope L; Li H; Jeschke J; Wang W; Baylin SB; Zahnow CA
    PLoS One; 2013; 8(7):e68630. PubMed ID: 23844228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.